sbla news - Search News

sBLA, Dupixent

Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA)

Monthly Prescribing Reference · 2d

FDA to Review Resubmitted Dupilumab sBLA for Chronic Spontaneous Urticaria

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

Pharmabiz · 3h

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin

Business Insider · 3d

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

MarketWatch · 2d

Regeneron, Sanofi Get New FDA Review of Dupixent for CSU

Regeneron Pharmaceuticals and Sanofi said the U.S. Food and Drug Administration has accepted their resubmitted application seeking expanded approval of the blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic spontaneous urticaria,

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

12h

This celebrity-approved SLBA anti-aging eye treatment is 40% off ahead of Black Friday — 'it really works,' say shoppers

One popular item that shoppers rave about is the celeb-approved Eye Lift Wand from SBLA Beauty. Marketed as "the first-ever ...

GlobalData on MSN5d

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Yahoo Finance3d

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results